As Artificial Intelligence continues to revolutionize the life sciences industry, companies must navigate both unprecedented opportunities and evolving regulatory considerations. With President Trump’s Executive Order on AI promoting a more flexible regulatory environment, the landscape is shifting toward industry-driven innovation. This panel will explore the latest advancements, key compliance risks, and how regulatory changes are shaping the future of AI in life sciences.

• Examining the latest ways that AI is being used to accelerate drug discovery, optimize clinical trials, enhance diagnostics, and improve patient outcomes
• Navigating FDA regulations and anticipating future AI-specific guidance for medical technologies
• Legislative efforts to modernize medical device regulations and AI’s role in shaping policy
• Intellectual property challenges and strategies for protecting AI-driven innovations